← All Grace Therapeutics, INC filings

Grace Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
GRCE
Grace Therapeutics, INC
10-K: Grace Therapeutics Faces FDA Setback for GTx-104
Grace Therapeutics reported a net loss for the fiscal year ended March 31, 2026, and received a Complete Response Letter from the FDA for its GTx-104 drug candidate.
NASDAQ
GRCE
Grace Therapeutics, INC
10-K: Grace Therapeutics Reports Positive Phase 3 Results for Lead Drug GTx-104, Eyes FDA Submission Amidst Continued Operating Losses
Grace Therapeutics, Inc. announced positive Phase 3 clinical trial results for its lead drug candidate, GTx-104, and plans for an FDA New Drug Application submission in the first half of calendar year 2025, despite reporting continued operating losses and a need for additional capital.
NASDAQ
GRCE
Grace Therapeutics, INC
10-K: Acasti Pharma Focuses on GTX-104 Development, Reports Fiscal Year 2024 Results
Acasti Pharma prioritizes its lead drug candidate, GTX-104, for aneurysmal subarachnoid hemorrhage, while reporting a reduced net loss for fiscal year 2024.